Mark Brosius Sells 28 Shares of Intuitive Surgical (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 28 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $360.21, for a total value of $10,085.88. Following the sale, the executive vice president directly owned 1,322 shares of the company’s stock, valued at approximately $476,197.62. The trade was a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Monday, July 27th, Mark Brosius sold 28 shares of Intuitive Surgical stock. The shares were sold at an average price of $344.00, for a total transaction of $9,632.00.
• On Friday, June 12th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The stock was sold at an average price of $414.13, for a total transaction of $10,353.25.
• On Wednesday, June 10th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The shares were sold at an average price of $424.14, for a total transaction of $9,755.22.
• On Monday, June 8th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $420.12, for a total value of $9,662.76.
• On Friday, May 22nd, Mark Brosius sold 18 shares of Intuitive Surgical stock. The stock was sold at an average price of $439.80, for a total value of $7,916.40.
• On Wednesday, May 20th, Mark Brosius sold 18 shares of Intuitive Surgical stock. The stock was sold at an average price of $440.38, for a total value of $7,926.84.
• On Monday, May 18th, Mark Brosius sold 18 shares of Intuitive Surgical stock. The shares were sold at an average price of $422.47, for a total value of $7,604.46.

Intuitive Surgical Stock Down 0.0%

ISRG opened at $352.97 on Friday. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The company has a 50-day simple moving average of $399.96 and a 200 day simple moving average of $452.67. The stock has a market capitalization of $124.70 billion, a price-to-earnings ratio of 40.43, a P/E/G ratio of 2.55 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.81 EPS. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ISRG. Royal Bank Of Canada lowered their target price on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Sanford C. Bernstein reduced their price target on shares of Intuitive Surgical from $750.00 to $685.00 and set an “outperform” rating on the stock in a research note on Friday, July 17th. HSBC lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price target on the stock. in a report on Thursday. The Goldman Sachs Group set a $558.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, May 27th. Finally, Truist Financial cut their target price on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Twenty research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $509.02.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: UBS upgraded ISRG, arguing that the selloff has been excessive. The call provides a counterpoint to recent target reductions and may support a rebound thesis as investors refocus on the company’s recurring instrument revenue and installed da Vinci system base. UBS upgrades Intuitive Surgical
• Positive Sentiment: Intuitive Surgical is expanding robotic-assisted surgery beyond its traditional urology strength, with general surgery and newer specialties offering additional long-term procedure growth opportunities. Robotic surgery expansion beyond urology
• Neutral Sentiment: HSBC downgraded ISRG from Buy to Hold but assigned a $391 price target, implying upside from recent levels. The mixed analyst signals reflect uncertainty about near-term growth rather than a fundamental change to the company’s long-term opportunity.
• Neutral Sentiment: Executive Vice President Mark Brosius sold small blocks of shares under a pre-arranged Rule 10b5-1 plan. The transactions totaled roughly $20,000 and reduced his holdings by about 2% in each sale, limiting their significance for investors. Intuitive Surgical insider sale
• Negative Sentiment: Investors remain concerned that U.S. procedure growth could soften and that deferred care may weigh on near-term utilization. Those concerns overshadowed the latest quarterly beat, in which revenue rose 18.4% year over year to $2.89 billion and EPS reached $2.80 versus the $2.48 consensus. Intuitive Surgical post-earnings selloff

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently made changes to their positions in ISRG. Prosperity Consulting Group LLC grew its holdings in Intuitive Surgical by 0.5% during the 3rd quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock worth $1,804,000 after acquiring an additional 19 shares during the period. Sunburst Financial Group LLC boosted its position in shares of Intuitive Surgical by 4.3% during the 4th quarter. Sunburst Financial Group LLC now owns 485 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 20 shares in the last quarter. WoodTrust Financial Corp boosted its position in shares of Intuitive Surgical by 0.5% during the 4th quarter. WoodTrust Financial Corp now owns 4,180 shares of the medical equipment provider’s stock valued at $2,367,000 after purchasing an additional 20 shares in the last quarter. North Star Investment Management Corp. grew its stake in Intuitive Surgical by 8.5% during the fourth quarter. North Star Investment Management Corp. now owns 269 shares of the medical equipment provider’s stock worth $152,000 after purchasing an additional 21 shares during the period. Finally, Cornerstone Planning Group LLC increased its holdings in Intuitive Surgical by 11.5% in the fourth quarter. Cornerstone Planning Group LLC now owns 203 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 21 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.